Physician-scientist and chief medical officer at Prime Medicine
Dr. Mohammed Asmal is Chief Medical Officer at Prime Medicine. He is a physician-scientist with an AB in biology and biomedical engineering from Harvard University, and an MD-PhD in molecular and cellular biology from Columbia University. He trained in internal medicine and infectious diseases at the Brigham and Women’s and Massachusetts General Hospitals, and has devoted much of his academic career to studying HIV, and to treating patients with infectious diseases. After leaving academic medicine, Dr. Asmal took on roles in clinical development at Vertex Pharmaceuticals, where he led trials in oncology and hepatitis C. He subsequently transitioned to bluebird bio, where he led the clinical development team, overseeing lentiviral-based gene therapy programs in rare disease and oncology, culminating in the first approval of a gene therapy for a hemoglobinopathy in the world. Immediately prior to joining Prime Medicine, Dr. Asmal was a venture partner at OrbiMed Advisors, LLC.